We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA plans to conduct two studies to gauge whether consumers and healthcare professionals have the capacity to detect and report deception prescription drug advertisements. Read More
Wockhardt is in hot water with the FDA again, receiving another warning letter for significant GMP violations regarding quality and data controls. Read More